Transscleral delivery of bevacizumab-loaded chitosan nanoparticles
Aşık, Mehmet Doğan
Çakmak, Hasan Basri
Denkbaş, Emir Baki
MetadataShow full item record
CitationUğurlu, N., Aşık, M. D., Çakmak, H. B., Tuncer, S., Türk, M., Çağıl, N., Denkbas, E. B. (2019). Transscleral delivery of bevacizumab-loaded chitosan nanoparticles. Journal of Biomedical Nanotechnology, 15(4), 830-838.
Purpose: The aim of this study was to synthesize bevacizumabloaded nanoparticles and evaluate their effects on the treatment of posterior segment diseases via subtenon injections. Methods: Bevacizumabloaded chitosan nanoparticles (BLCNs) were synthesized by the ionic gelation method, and their physicochemical characteristics and in vitro release profile were studied. The BLCNs were characterized using atomic force microscopy (AFM), FTIR spectroscopy, dynamic light scattering, and scanning electron microscopy. The BLCNs were delivered into rabbits eyes via posterior subtenon injections. An immunohistochemical evaluation of the ocular tissues was performed, and the vitreous humor and serum bevacizumab levels were measured by ELISA. Results: Bevacizumabloaded chitosan nanoparticles with a diameter of 80 to 380 nm were prepared and characterized. In vitro studies showed that after the first 5 days of the experiment, a significant increase in the drug release maintained the desired drug dosage for 3 weeks. Immunohistochemical in vivo studies revealed that there were BLCNs penetrating through the sclera. Furthermore, the intravitreal bevacizumab concentration reached a maximum concentration of 18 gml, and it decreased to 6 gml after only a week. Conclusion: The results revealed that subtenon injection of BLCNs is a promising alternative to intravitreal injections. In addition to the ELISA studies, immunohistochemical experiments confirmed that BLCNs enable transscleral bevacizumab penetration, and BLCN usage may provide the required bevacizumab levels for the treatment of posterior segment diseases. © 2019 American Scientific Publishers